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Abstract
Aim—We investigated candidate genes associated with thiopurine metabolism and clinical
response in childhood acute lymphoblastic leukemia.
Materials & methods—We performed genome-wide SNP association studies of 6-thioguanine
and 6-mercaptopurine cytotoxicity using lymphoblastoid cell lines. We then genotyped the top
SNPs associated with lymphoblastoid cell line cytotoxicity, together with tagSNPs for genes in the
‘thiopurine pathway’ (686 total SNPs), in DNA from 589 Caucasian UK ALL97 patients.
Functional validation studies were performed by siRNA knockdown in cancer cell lines.
Results—SNPs in the thiopurine pathway genes ABCC4, ABCC5, IMPDH1, ITPA, SLC28A3 and
XDH, and SNPs located within or near ATP6AP2, FRMD4B, GNG2, KCNMA1 and NME1, were
associated with clinical response and measures of thiopurine metabolism. Functional validation
showed shifts in cytotoxicity for these genes.
Conclusion—The clinical response to thiopurines may be regulated by variation in known
thiopurine pathway genes and additional novel genes outside of the thiopurine pathway.
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The thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used in the
consolidation and maintenance phases of treatment protocols for childhood acute
lymphoblastic leukemia (ALL) [1]. 6-MP is the established thiopurine in the maintenance
phase; when used during maintenance therapy 6-TG carries a greater risk of severe adverse
effects [2,3] but, it may be more effective for specific subgroups of patients [1]. Although
these drugs represent an important component of the pharmacologic therapy of this disease,
there are wide variations in efficacy and their use carries a risk of myelosuppression and, in
some protocols, secondary neoplasia [4–9]. Pharmacogenomics, the study of the role of
inheritance in variation in drug response phenotypes [10], may help us better understand and
predict individual variation in the occurrence of both adverse drug responses and relapse
during the treatment of childhood ALL. Previous studies of thiopurine pharmacogenomics
have focused on SNPs in ‘thiopurine pathway’ genes [11], such as TPMT, an enzyme that
catalyzes the S-methylation of thiopurines [4]. Polymorphisms in the gene encoding this
enzyme are associated with elevated levels of the active thiopurine metabolites, 6-TG
nucleotides (6-TGNs), and, as a result, with myelosuppression [12,13]. Therefore,
genotyping of TPMT or measuring red blood cell (RBC) TPMT enzyme activity are used
clinically to help optimize thiopurine therapy [4,14].
Altered thiopurine disposition has also been reported to be associated with polymorphisms
in a number of candidate genes [15]. Polymorphisms in the gene encoding the ABCC4 drug
transporter [16–18] and in the ITPA gene have been associated with neutropenia and
thrombocytopenia during thiopurine therapy [19,20]. Although somatic ‘tumor’ mutations
obviously influence response to drug therapy, thiopurine pharmacogenetics (e.g., TPMT)
serves to emphasize the fact that germline polymorphisms can also play an important role in
drug response [10]. However, the possible contribution of nonthiopurine pathway genes to
variation in thiopurine response remains unclear. A number of genome-wide association
studies (GWAS) have reported germline SNPs associated with the risk for the occurrence of
ALL [21–23] and ALL treatment response phenotypes [24–27]. Germline GWAS studies
have identified SNPs associated with relapse risk in methotrexate, dexamethasone and
asparaginase pharmacologic phenotypes [26] and, with respect to thiopurine metabolism,
SNPs associated with modulations in TPMT activity [27].
Focusing on thiopurine metabolism, we had previously utilized a cellular model system that
consists of a large panel of lymphoblastoid cell lines (LCLs) for which we have generated
dense genomic data, both SNPs and expression array data, to study the cytotoxicity of both
6-MP and 6-TG [28,29]. Specifically, we associated 6-MP and 6-TG cytotoxicity (i.e., IC50)
values with genome-wide expression array data. As a result of those studies we reported a
novel ‘cellular circulation’ of thiopurines that involved extrusion of nucleotide
monophosphates by ABCC4, hydrolysis of the nucleotides outside of the cell by the ecto-
enzyme NT5E and transport of the resultant nucleosides back into the cell by SLC29 [30].
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The LCL model system used to perform those studies has repeatedly proven to be a
powerful tool for both generating pharmacogenomic hypotheses and for pursuing SNP
signals identified during clinical GWAS [28,29,31–34].
In the present study, we followed up our previous report using expression array data but, this
time utilizing SNP association data from the same LCLs. Specifically we have applied a
‘three-tiered’ experimental strategy to investigate candidate genes associated with clinical
response in patients with childhood ALL. We began with studies of 176 LCLs from the
ethnically diverse Coriell ‘Human Variation Panel’ [30,35] for which we had performed
GWAS of the association of SNPs and gene expression with 6-TG and 6-MP cytotoxicity
(IC50 values) [30]. As the second step, we genotyped SNPs identified during the SNP
GWAS performed with the LCLs as well as thiopurine pathway gene tagSNPs using DNA
from Caucasian children with ALL who were enrolled in the UK ALL97 clinical trial. We
observed novel associations for several of these SNPs with clinical measures of treatment
response, disease outcome and thiopurine metabolite concentrations. For the third step,
candidate genes identified by genotyping clinical DNA samples from the ALL patients were
selected for functional validation, which was performed by determining the effect of siRNA
gene knockdown on 6-MP and 6-TG cytotoxicity studies in cancer cell lines.
Materials & methods
Cell lines
LCLs from 58 African–American, 58 European–American, and 60 Han Chinese–American
unrelated healthy subjects (sample sets HD100AA, HD100CAU and HD100CHI) were
purchased from the Coriell Cell Repository (NJ, USA). These cell lines had been generated
from blood samples collected and anonymized by the National Institute of General Medical
Sciences (NIGMS). All subjects had provided written consent for the use of their samples
for research purposes. This study was reviewed and approved by the Mayo Clinic
Institutional Review Board. HeLa (human cervical carcinoma), U87MG and U251 (human
glioma) as well as OVCAR10 (ovarian cancer) cell lines were purchased from the American
Type Culture Collection (VA, USA).
Drugs & cell proliferation assays
6-MP and 6-TG were purchased from Sigma Aldrich (MO, USA). Cytotoxicity assays were
performed using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay
(Promega Corporation, WI, USA) after 72 h drug exposure over a range of drug
concentrations (see Supplementary table 1 at www.futuremedicine.com/doi/suppl/10.2217/
pgs.13.266 for concentrations) for lymphoblastoid, HeLa, OVCAR10, U87MG and U251
cell lines.
LCL genomic data
DNA from the Human Variation Panel LCLs had been genotyped in the Mayo Clinic
Genotype Shared Resource (GSR) using Illumina HumanHap 550K and 510S BeadChips.
The Coriell Institute also genotyped and made available Affymetrix SNP Array 6.0 Chip
data for these cell lines. As a result, approximately 1.3 million unique SNPs were available
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for each cell line. Total RNA was also extracted from each of the LCLs using the Qiagen
RNeasy Mini kit (Qiagen, Inc., CA, USA) and RNA quality was tested using an Agilent
2100 Bioanalyzer, followed by hybridization to Affymetrix U133 Plus 2.0 GeneChips. Basal
mRNA expression data were normalized using guanine cytosine robust multiarray analysis
[36]. These data are available in the NCBI database under accession number GSE24277. In
an analysis of 1.3 million SNPs one would predict 130 SNPs to be associated with 6-TG or
6-MP IC50 at a 1 × 10−4 level. No adjustment was made for multiple testing, although a
conservative Bonferroni cutoff of p < 7.28 × 10−5 would account for the 686 SNPs analyzed.
For these reasons SNPs with an association <1 × 10−4 were considered for further study.
UK ALL97 clinical trial
The UK Medical Research Council (MRC) ALL97 trial (UK ALL97, registration number
ISRCTN26727615) compared the efficacy and toxicity of dexamethasone and 6-TG
(experimental arm) with prednisone and 6-MP (standard approach arm). This trial recruited
ALL patients aged 1–18 years who were newly diagnosed with their first episode of ALL.
The patients were diagnosed in the UK and Ireland between January 1997 and June 2002.
Patient ethnicity was recorded at trial recruitment by asking the parents. Treatment centers
obtained local ethics committee approval and informed consent from patients and/or parents.
The trial included an add-on pharmacogenetic and drug metabolism study designed to
investigate inter- and intra-patient variability in response to thiopurines. Background
treatment regimens underwent several modifications during the trial, but randomizations and
biological studies were retained. Patients were randomly allocated to daily oral 6-TG
(standard dose 40 mg/m2) or 6-MP (standard dose 75 mg/m2) during interim and continuing
maintenance. Thiopurine doses were titrated to achieve target neutrophil and platelet counts.
Details of the titration protocols, treatment regimens and modifications have been reported
previously [3,37].
Blood samples were requested at disease diagnosis and during thiopurine maintenance
chemotherapy. During maintenance chemotherapy, blood samples were obtained after at
least 7 days at the standard protocol thiopurine dose or at the maximum tolerated dose, but
not within 2 months of a red cell transfusion. Blood samples were obtained at the earliest
convenient time point after the criteria described above were met. If maintenance therapy
had been interrupted or the dosage reduced, the sample was obtained after the recovery of
cell counts during the next cycle of thiopurine therapy. The use of these DNA samples and
associated clinical data to perform the present study was reviewed and approved by the
Sheffield Local Research Ethics Committee (reference 08/H1308/279).
TPMT activity & thiopurine metabolite assays
The concentrations of the 6-TGN and methyl-mercaptopurine nucleotide (MeMPN)
thiopurine metabolites and TPMT activity were measured by HPLC, as described previously
[38,39]. The TPMT activity assay was modified to measure the methylmercaptopurine
product directly [2]. Metabolite assay results are reported as pmol/8 × 108 RBCs and TPMT
activity as units/ml packed RBCs.
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Genotyping
DNA extracted from blood samples (Nucleon BACC1, Manchester, UK) was genotyped for
TPMT*3A, TPMT*3B and TPMT*3C by amplification of exons 7 and 10 using intron-based
primers [40]. A 10 μl aliquot of the PCR product was digested for 4 h with Mwo1 at 60°C to
detect TPMT*3B (wild-type fragments 226 bp and 100 bp, variant allele, 326 bp, not
digested) and Acc1 at 37°C to detect TPMT*3C (wild-type, 437 bp, not digested, variant
allele fragments 268 bp and 169 bp). TPMT*3A is a double mutant containing both the exon
7 and exon 10 variant alleles. The restriction digestion products were analyzed on 4% poly-
acrylamide gels. TPMT*2 was determined by sequencing exon 5 of the TPMT gene using an
ABI 3730 capillary sequencer (Applied Biosystems, Warrington, UK) with dye-primer
chemistry. SNPs selected for genotyping using DNA from the ALL97 patients were quality-
tested by Illumina, arranged in a customized genotyping panel and genotyped using the
Illumina GoldenGate system (CA, USA).
Transient transfection & RNAi
siRNAs used to perform the gene knockdown studies were purchased from Dharmacon
RNAi Technologies (CO, USA). The cell lines studied were transfected with
Lipofectamine™ RNAiMAX (Invitrogen, CA, USA). Briefly, approximately 4–5 × 103 cells
were plated in a 96-well format and were transfected with 5 nM of the appropriate siRNA.
After 24 h, a series of drug concentrations was added, followed by incubation for 72 h.
Cytotoxicity was measured as described previously, and total RNA was isolated from the
cells using the Qiagen RNeasy kit. Primers were purchased from Qiagen, and quantitative
reverse transcription (qRT)-PCR was performed using the one-step, Brilliant SYBR® Green
qRT-PCR master mix kit (Stratagene, CA, USA) with the StepOnePlus™ Real-Time PCR
System (Applied Biosystems, CA, USA). All experiments were performed in triplicate with
β-actin as an internal control. The efficiency of siRNA knockdown was estimated by
quantitative PCR, comparing the mRNA expression of the siRNA knockdown genes with
nontargeting siRNA as a control. The nontargeting siRNA was designed to target no known
genes in the human cells lines and so determine baseline gene-expression levels. The
efficiency of gene-expression knockdown ranged from 70–90%.
Statistical methods & association analysis
The statistical methods for LCL analysis, including adjusting for ethnicity, have been
previously described [30]. For the functional validation studies best fit curves, before and
after gene knockdown, were fitted using GraphPad Prism Software (CA, USA). The data
was fitted to a four parameter nonlinear regression, curve fit, model selecting a variable
slope and sigmoidal dose–response curve. Statistical significance was calculated using the
Student’s t-test for paired data in the GraphPad software. Survival was calculated from the
start of treatment to death or last follow-up, while relapse-free survival was calculated from
start of treatment to relapse/death, or last follow-up. Association of survival and relapse
phenotypes and SNPs was assessed using Cox proportional hazard models. All other
phenotypes were transformed because of skewness, using a van der Waerden rank
transformation, and association with SNPs was assessed using linear regression. Increase in
model R2 was derived from the difference in model R2 by adding genotype beyond
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covariates, and direction of the genotype effect was the sign of the effect of the genotype in
the regression model. All analyses were adjusted for TPMT ‘metabolizer status’, and the
treatment received. SNP genotypes were modeled with an additive genetic model (count of
rare alleles).
Results
For the thiopurine studies, within the UK ALL97 clinical trial, 87% of the patients enrolled
were Caucasian and 13% belonged to other ethnic groups (5.4% Asian [Indian or Pakistani
decent], 3.3% mixed race, 1.5% black, 0.5% Oriental and 2.3% unknown or non-Caucasian).
Analysis was restricted to the Caucasian cohort; blood and DNA samples were obtained
from 589 Caucasian children. Demographic data for these patients are summarized in table
1. The SNPs genotyped using DNA samples from these patients were selected from two
sources: SNPs identified during 6-TG and 6-MP cytotoxicity GWAS conducted with the
Human Variation Panel of LCLs; and tagSNPs for genes encoding proteins in the thiopurine
pathway as defined by PharmGKB [101].
Subsequent paragraphs describe first, the Human Variation Panel LCL Model System
GWAS that was used to identify the majority of SNPs used to genotype the clinical samples;
second the results of the clinical sample genotyping; and, third, the functional validation of
selected genes related to SNPs that displayed associations with the clinical phenotypes
studied.
Human Variation Panel 6-TG & 6-MP cytotoxicity GWAS
The Manhattan plots for the LCL thiopurine GWAS, depicted graphically in Figure 1,
showed that 153 SNPs with p < 1 × 10−4 were associated with 6-TG IC50 values and 130
with 6-MP IC50 values, but only six of those SNPs were common to both drugs (Figure 1C).
All SNPs with p < 1 × 10−4 for both LCL 6-TG and 6-MP GWAS are listed in
Supplementary tables 2a & 2b, with an asterix indicating SNPs that were common to both 6-
TG and 6-MP. The top SNP for 6-TG cytotoxicity was rs6097295 (p = 2.34 × 10−7, r =
0.40). This SNP mapped to chromosome 20 (Figure 1a) in the first intron of the TSHZ2 gene
and the variant allele for this SNP was associated with increased resistance. Two other SNPs
with low p-values mapped to the same TSHZ2 intron. The most striking SNP signal
observed in the 6-MP GWAS mapped to chromosome 17 (Figure 1b), with the top SNP,
rs4794227 (r = −0.38; p = 1.31 × 10−6), located in the 3′-UTR of the UTP18 gene. The
variant allele for this SNP was associated with decreased 6-MP IC50, that is, enhanced
sensitivity.
SNPs with p-values <1 × 10−4 from the LCL GWAS (Figure 1C) as well as a group of
tagSNPs for thiopurine pathway genes were then genotyped using DNA samples from
patients enrolled in the UK ALL97 trials [3]. A graphical outline of the process of SNP
selection is shown in Figure 2. Specifically, 403 SNPs were selected from the 6-TG and 6-
MP LCL GWAS (p < 1 × 10−4; Supplementary tables 2a, 2b, Figure 1C & Figure 2a). That
number included 114 from the SNP peak on a 380 kb region of chromosome 17 observed
during the 6-MP GWAS (Figure 1b). SNPs with low p-values within this region other than
those genotyped during the GWAS were imputed using CEU HapMap 3 data. The
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PharmGKB database and HapMap 2 data were used to select an additional 387 thiopurine
pathway tagSNPs (Figure 2b). Therefore, 790 SNPs were submitted to Illumina, and a final
total of 686 SNPs passed quality control, were successfully genotyped using DNA from UK
ALL97 patients and were analyzed for their possible association with clinical phenotypes.
Association analysis for UK ALL97 patients
Possible associations between the SNPs genotyped in the 589 patients studied and patient-
related phenotypes were investigated. These phenotypes included patient RBC TPMT
activities at both disease diagnosis and relapse, patient RBC drug metabolite concentrations
(6-TGNs and MeMPNs), disease relapse and patient survival. It should be noted that some
of the DNA samples had been obtained at the time of initial diagnosis while others were
obtained during remission maintenance chemotherapy. For the survival, relapse and TPMT
activity phenotypes, genotypes from both ‘diagnosis’ and ‘chemotherapy’ samples were
used to perform the association analyses, while – for obvious reasons – only genotypes from
the chemotherapy samples could be used to perform association analyses for 6-TGN and
MeMPN concentrations or the MeMPN:6-TGN ratio because those phenotypes were only
available after the initiation of chemotherapy. Comparison of genotypes showed a 99%
concordance between genotypes for diagnosis and chemotherapy samples from the patients
for which both types of DNA samples were available (n = 104). Although there is good
agreement between the genotypes, it is not complete. For this reason, because the at
diagnosis genotype sample was derived from white blood cells containing predominantly
leukemic cells, the diagnosis and chemotherapy samples were analyzed separately in the
association analysis of survival and relapse. tables 2 & 3 summarize the association of SNPs
and clinical phenotypes.
TPMT genotype associations
TPMT genotype is associated with striking variation in TPMT activity and, as a result, with
risk for the occurrence of serious adverse drug reactions in patients treated with thiopurines
[4]. Our association analysis (Supplementary table 3) confirmed that TPMT genotype was
highly associated with level of TPMT activity during chemotherapy (2.90 × 10−43), RBC
MeMPN:6-TGN ratio (5.63 × 10−6) and RBC 6-TGN concentrations (p = 1.62 × 10−6) in
these patients. However, TPMT genotype (analyzed as wild-type or variant allele) was not
significantly associated with either survival or relapse (Supplementary table 3). The ALL97
protocol adjusted drug dose in TPMT deficient patients to a starting dose of 10% of the
standard 75 mg m−2 protocol dose. For all patients the thiopurine dose was titrated to target
blood cell counts for a degree of controlled myelosuppression. A small cohort of problem
patients (drug sensitivity or nonresponse) had thiopurine dosage adjusted based on drug
metabolite levels. This lack of association of TPMT with outcome measures has been
observed in similar protocols [41]. In order to determine whether additional SNPs, beyond
those in TPMT, might be associated with clinical phenotypes in ALL patients, association
analyses were performed after adjusting for TPMT genotype and TPMT enzyme activity as
covariates. Since results adjusted for TPMT genotype and TPMT enzyme activity during
chemotherapy did not differ significantly, in subsequent paragraphs we will only report
results adjusted for TPMT genotype.
Matimba et al. Page 7
Pharmacogenomics. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Associations with treatment outcomes
Included among the strongest associations with treatment outcomes were those seen for the
rs7321807 and rs7325256 (linkage disequilibrium r2 = 1) SNPs in the thiopurine pathway
gene ABCC4, with hazard ratio values of 6.28 and 4.48 for relapse and survival, respectively
(tables 2 & 3). A hazard ratio >1 indicates a worse survival or an increased risk of relapse.
Other thiopurine pathway SNPs associated with these clinical disease-related outcomes
mapped to the introns of ABCC5, IMPDH1, ITPA and XDH. An intronic SNP in ITPA,
rs7270101, previously reported to be associated with thiopurine metabolism and febrile
neutropenia in US ALL patients [20] and a poorer event-free survival in Asian ALL patients
[42], was also associated with increased risk for relapse in the ALL97 patients (tables 2 &
3).
Nonthiopurine pathway SNPs associated with the survival and relapse phenotypes were
located in or near the ZP4, RAD51AP2, VSNL1, A2BP1 and MAPK4genes (tables 4 & 5).
Since these SNPs had been selected from among top SNPs associated with 6-TG and 6-MP
IC50 values observed during the LCL GWAS, and since SNPs that were positively
associated with IC50 values during those studies would be expected to be related to drug
resistance, potentially resulting in worse outcomes (hazard ratio >1), the results listed in
table 4 & 5 for outcomes were all compatible with predictions from the LCL thiopurine
cytotoxicity GWAS.
Associations with RBC TPMT activity & thiopurine metabolite concentrations
Reductions in on-chemotherapy RBC TPMT activity were associated with SNPs in introns
of the thiopurine pathway genes XDH, IMPDH1, SLC28A3 and ABCC4 (tables 2 & 3). A
SNP in the nonthiopurine pathway gene FAM8A6P (rs1040637) was associated with
increased TPMT activity, while rs200148, which mapped between AIG1 and HIVEP2
(tables 4 & 5), was associated with reduced enzyme activity. In the LCLs, the rs200148 SNP
was associated with increased sensitivity to 6-TG and 6-MP, as would be expected for a
reduction in TPMT activity [4].
As anticipated [4], levels of 6-TGNs, active thiopurine metabolites, were negatively
correlated with on-chemotherapy TPMT activity (6-MP: rS = −0.247, p ≤ 0.0001, 6-TG: rS =
−0.266, p ≤ 0.0001). 6-TGN and MeMPN concentrations and the MeMPN:TGN ratio were
associated with SNPs in the thiopurine pathway genes TPMT, ABCC4 and in SLC28A3
(tables 2 & 3). Intronic SNPs in the nonthiopurine pathway genes CDH12, FRMD4B and
GNG2 were associated with reduced levels of MeMPNs (p < 0.01). SNPs that mapped to
KCNMA1 and PAG1 were associated with increased 6-TGN levels in patients treated with 6-
MP (tables 4 & 5).
SNP associations with gene expression
Since SNPs can regulate gene expression in either a cis or trans fashion [35], we took
advantage of the LCL model system, with the full realization that LCLs are not
lymphoblasts, to test for associations of SNPs that were associated with clinical phenotypes
(tables 2, 3, 4 & 5) with mRNA expression data in the Human Variation Panel LCLs
(Supplementary table 4). For example, the ITPA intronic SNP rs7270101 was associated (p
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= 5.07 × 10−9) with reduced expression of its gene. These observations confirmed a previous
report that this SNP altered splicing and was associated with decreased ITPA expression and
decreased ITPA enzyme activity [43]. The rs7321807 and rs7325256 SNPs in ABCC4 were
in linkage disequilibrium (r2= 1) and were associated (p = 3.37 × 10−3 and 3.90 × 10−3) with
increased expression of ABCC4 in LCLs (Supplementary table 4). These associations for
ABCC4 SNPs were not significant after correcting for multiple comparisons, but their
possible functional role was supported by their association with worse clinical outcomes for
the UK ALL97 patients (tables 2 & 3). By studying possible trans expression associations
for SNPs, we found that rs200148 in the region between HIVEP2 and AIG1 was associated
with both reduced TPMT activity (table 5) and with expression of the thiopurine pathway
genes ADA (p = 7.39 × 10−4) and GART (p = 1.46 × 10−7; Supplementary table 4).
Candidate gene functional validation
As the final step in our series of experiments, we selected a panel of genes to study for their
effects on thiopurine cytotoxicity in cancer cell lines as a functional test of the associations
that we had observed. Genes were selected for functional validation if SNPs associated with
at least one phenotype with p < 0.01 (tables 2, 3, 4 & 5) were located in or near (<200 kb)
that gene. GWAS identified six SNPs associated with both 6-TG and 6-MP cytotoxicity,
functional validation was performed for two of these (CCND2 and C10orf118) together with
SNPs associated with clinical outcome. We did not prioritize pseudo-genes or genes without
names, rather we investigated SNPs in known functional genes. The ADA and GART genes
were added as a result of our trans expression association analysis of top SNPs in the LCLs
(Supplementary table 4). A total of 21 genes were selected for functional testing. Each of
these genes was required to be expressed in at least two tumor cell lines out of a panel
composed of HeLa, OVCAR10, U251 and U87MG. We first obtained basal expression array
data for all four cell lines. In order to proceed with testing, we required an intensity level
that indicated sufficient mRNA for siRNA gene knockdown to be meaningful and for qRT-
PCR to measure both basal gene expression and the efficiency of siRNA knockdown.
Validation required that siRNA knockdown result in a significant shift of the cytotoxicity
curve for at least two cell lines. For example, after the knockdown of ATP6AP2, FRMD4B,
GNG2, KCNMA1, UTP18 and NME1, the cell lines were more resistant to both drugs
(Figure 3). Functional validation of thiopurine pathway genes showed significant shifts of
cytotoxicity curves in the anticipated direction (p < 0.05) for TPMT and ITPA (Figure 3) as
well as ABCC4, ADA and SLC28A3 in HeLa cells (Supplementary Figure 1). The anticipated
increase in sensitivity was observed after TPMT knockdown, while increased resistance was
observed after SLC28A3 knockdown – as anticipated based on our previous LCL-expression
studies [30]. The overall results of the functional analyses are summarized in Supplementary
table 5.
Discussion
We have applied a ‘three-tiered’ experimental strategy in an attempt to identify and
functionally validate novel associations of SNPs, and their corresponding genes, with
variation in thiopurine response phenotypes in UK ALL97 patients. The SNPs were initially
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identified on the basis of 6-TG and 6-MP cytotoxicity GWAS performed with LCLs or as
tagSNPs for thiopurine pathway genes. Obviously, p-values of 1 × 10−4 during the LCL
GWAS were not genome-wide significant after correction for multiple comparisons, but the
purpose was to identify ‘candidate’ SNPs to test by genotyping clinical samples to determine
whether they might be associated with clinical phenotypes for ALL patients treated with
thiopurines. It should be emphasized that all of these patients were treated with thiopurines,
but they were also treated with several other drugs. We anticipated, correctly, that
associations determined using clinical samples would probably be inconclusive, which is
why we also included a final functional validation step for candidate SNPs associated with
clinical phenotypes as the final step in our three-tiered strategy.
The LCL studies identified only six SNPs associated with both 6-TG and 6-MP IC50 values.
This is perhaps a direct reflection of the differing activation pathways for the two
thiopurines (6-TG forms TGNs directly whereas 6-MP forms a variety of nucleotide
metabolites prior to TGN formation), coupled to the limitations of studying drug metabolism
in a cell-line system, a system that cannot reflect the presystemic metabolism and intra- and
inter-cellular drug metabolite transfer that occurs in vivo. Therefore the LCL model system
is of greatest value for the study of pharmacodynamic effects rather than pharmacokinetic
effects. Because the LCL system is unable to address many genes encoding proteins
involved in pharmacokinetics we added tagSNPs for thiopurine pathway genes when we
analyzed the clinical samples. In our validation studies, when we knocked-down both
thiopurine pathway and nonthiopurine pathway genes, we found that 20 (out of 25 genes
tested) altered the resistance to both 6-TG and 6-MP.
The most significant associations observed were for intronic SNPs in SLC28A3 with reduced
6-TGN levels and MeMPN:6-TGN ratios during 6-MP therapy and for ABCC4 intronic
SNPs with relapse and survival (tables 2 & 3). Knockdown of SLC28A3 resulted in
increased drug resistance (Supplementary Figure 1). A large number of SNPs associated
with treatment outcome in ALL97 patients mapped to genes encoding the ABCC4 and
ABCC5 transporters (tables 2 & 3). These genes encode proteins that can extrude nucleotide
monophosphates from the cell [16,30]. Increased expression of ABCC4 is associated with
the rs7321807 and rs7325256 SNPs (Supplementary table 4), which may explain drug
resistance with increased risk of relapse, as observed in this study. As anticipated,
knockdown of ABCC4 in HeLa cells resulted in lower IC50 values and increased thiopurine
sensitivity (Supplementary Figure 1), in agreement with results reported by Krishnamurthy
et al. and Li et al., both of whom showed that decreased expression of ABCC4 results in the
intracellular accumulation of 6-TGNs and increased drug sensitivity [16,30].
The rs7270101 SNP in ITPA has been reported to alter splicing and is associated with
decreased ITPA expression and enzyme activity [43], resulting in the accumulation of
thioinosine triphosphate and reduced production of 6-TGNs. Our knockdown of ITPA
(Figure 3) resulted in increased IC50 values in OVCAR10 and U251 cells, demonstrating
that reduced ITPA expression in tumor cells results in thiopurine resistance. These
observations may be related to both the increased risk of relapse in the patients in this study
who carried this polymorphism (tables 2 & 3) and to the decreased survival associated with
ITPA polymorphisms reported in Asian ALL patients [42].
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TPMT enzyme activity is inversely correlated with 6-TGN levels [4]. Reduced RBC 6-TGN
concentrations as a result of elevated TPMT activity may increase the risk of relapse [44],
while high levels of 6-TGNs may result in myelosuppression [4,8]. However, SNPs located
in regions of the genome other than TPMT itself may also influence level of TPMT activity
[27,45]. For example, we observed an association of reduced TPMT activity with the
rs200148 SNP that lies between AIG1 and HIVEP2 (tables 4 & 5). This SNP was also
negatively associated with expression of the thiopurine pathway gene ADA in LCLs
(Supplementary table 4). We also showed that siRNA knockdown of ADA resulted in
increased sensitivity to 6-TG and 6-MP in HeLa cells (Supplementary Figure 1), similar to
the effect of TPMT knockdown. Although it was not possible to perform siRNA knockdown
for all of the candidate genes that we identified, we did show that knockdown of ATP6AP2,
GNG2, FRMD4B, NME1, KCNMA1 and UTP18 resulted in increased resistance to
thiopurine drug-induced cytotoxicity (Figure 4 & Supplementary table 5). Possible
mechanisms responsible for these observations should be pursued in the course of future
studies.
It should be emphasized that LCLs, like all model systems, have limitations. However, it
should be emphasized once again that this LCL model system has already repeatedly
demonstrated its power to generate pharmacogenomic hypotheses [28,32,33,46] and to
pursue pharmacogenomic hypotheses from clinical GWAS [31,34,47]. The present study
shows that SNPs identified during GWAS performed with this model system may help lead
us to genomic regions of possible importance for thiopurine treatment response. It should
also be emphasized, as pointed out earlier, that mutations in the tumor genome obviously
play a critical role in variation in antineoplastic drug response, but our studies show that
germline polymorphisms can also play an important role in variation in response to
antineoplastic drug therapy [10].
In summary, we have applied a three-tiered research strategy to identify, test using clinical
samples, and functionally validate the relationships among SNPs, clinical outcomes, gene
expression and the cytotoxicity of thiopurine drugs used to treat childhood ALL. We
observed a series of novel associations with clinical response phenotypes in ALL patients,
but few of these associations were significant after correcting for multiple comparisons (p <
7.1 × 10−5). That is why our use of a three-step research strategy, utilizing three different
systems, was essential. We used HeLa, U251, U87M and OVCAR10 cancer cell lines for
the final functional validation; chosen because the target genes were expressed in these cell
lines and their use was without the technical difficulties associated with validation in
nonadherent cell lines.
Conclusion
In conclusion, the results of the studies described here contribute to our understanding of the
pharmacogenomics of thiopurine response in the therapy of childhood ALL. We did not
identify any new, strong candidate genes but confirmed earlier reports of the functional
importance, and impact, of genes in the thiopurine pathway – especially ABC and SLC
transporter genes – and added novel nonthiopurine pathway candidate genes of potential
importance for clinical drug-response phenotypes. These results may also point to a future in
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which panels of biomarkers might help to better optimize and monitor thiopurine therapy of
childhood ALL.
Future perspective
Our study has shown that germline polymorphisms can play an important role in the
variation in response to the chemotherapy of childhood ALL. We specifically concentrated
on the response to thiopurine therapy because, for many successful ALL protocols,
thiopurine maintenance chemotherapy is the backbone of the long-term (2 to 3 years)
continuing chemotherapy. Treatment outcome after disease relapse remains poor and so the
delivery of optimum drug therapy in first remission is of prime importance. The most
significant associations with treatment outcome were observed for SNPs in the genes
encoding ABC and SLC transporters: a large number of SNPs mapped to genes encoding
ABCC4 and ABCC5, observations that confirm earlier reports of their clinical importance.
Also within genes influencing thiopurine metabolite formation, we observed an increased
relapse risk with the rs7270101 ITPA polymorphism and reduced ITPA expression in the
knockdown studies resulted in increased thiopurine resistance. These results indicate SNPs
that could modulate the response to thiopurine drugs and future studies should investigate
these SNPs as a biomarker panel, along with indices of TPMT status and thiopurine
metabolite formation, which could be used to optimize the delivery of thiopurine drugs.
Potentially, the biomarkers could identify thiopurine ‘good response’ patients in whom the
intensity of total chemotherapy could potentially be reduced and vice versa, the
identification of thiopurine nonresponders who may require additional risk-directed
intensification of therapy.
Additionally, our studies showed that knockdown of ATP6AP2, GNG2, FRMD4B, NME1,
KCNMA1 and UTP18, genes that were associated with clinical phenotypes but not directly
associated with thiopurine metabolism or recirculation, resulted in an increased resistance to
thiopurine drug-induced cytotoxicity. Possible mechanisms responsible for these
observations should be pursued in the course of future studies; this may enable an increased
understanding of the underlying processes that play a role in thiopurine response and
treatment outcome.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors wish to thank all the clinicians who entered patients into UK ALL97 and the participating children and
their families. The authors thank the Clinical Trials Service Unit, University of Oxford, for patient outcome and
demographic data and the UK Medical Research Council funded UK Childhood Leukaemia Working Party, which
oversaw recruitment to the trial and enabled the thiopurine studies. The authors thank L Wussow for her assistance
with the preparation of this manuscript.
References
Papers of special note have been highlighted as:
Matimba et al. Page 12
Pharmacogenomics. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
▪ of interest
▪▪ of considerable interest
1. Escherich GM, Richards S, Stork LC, Vora AJ. Meta-analysis of randomised trials comparing
thiopurines in childhood acute lymphoblastic leukaemia. Leukemia. 2011; 25:953–959. [PubMed:
21372841]
2. Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS, Vora A. The thiopurine
methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive
disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2006;
80(4):375–383. [PubMed: 17015055]
3. Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-
mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 2006;
368(9544):1339–1348. [PubMed: 17046466]
4▪▪. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights,
challenges and future directions. Oncogene. 2006; 25(11):1629–1638. Key conclusions with
respect to the TPMT genetic polymorphism. Discusses unresolved issues and areas for future
emphasis. [PubMed: 16550163]
5. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic
leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug
chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010; 28(14):2339–2347.
[PubMed: 20385996]
6. Schmiegelow K, Al-Modhwahi I, Andersen MK, et al. Methotrexate/6-mercaptopurine maintenance
therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic
leukemia: results from the NOPHO ALL-92 study. Blood. 2009; 113(24):6077–6084. [PubMed:
19224761]
7. Lund B, Asberg A, Heyman M, et al. Risk factors for treatment related mortality in childhood acute
lymphoblastic leukaemia. Pediatric Blood Cancer. 2010; 56(4):551–559. [PubMed: 21298739]
8. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between
intracellular 6-mercaptopurine metabolites and neutropenia. 1983. Br J Clin Pharmacol. 2004;
58(7):S867–S871. discussion S872–S864. [PubMed: 15595985]
9. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005; 131(5):
579–587. [PubMed: 16351633]
10. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;
364(12):1144–1153. [PubMed: 21428770]
11. Zaza G, Cheok M, Krynetskaia N, et al. Thiopurine pathway. Pharmacogenet Genomics. 2010;
20(9):573–574. [PubMed: 19952870]
12. Lennard L, Lewis IJ, Michelagnoli M, Lilleyman JS. Thiopurine methyltransferase deficiency in
childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies. Med Pediatr Oncol.
1997; 29(4):252–255. [PubMed: 9251729]
13. Lennard L. The clinical pharmacology of 6-mercaptopurine. Euro J Clin Pharmacol. 1992; 43(4):
329–339.
14▪▪. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation
Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin
Pharmacol Ther. 2011; 89(3):387–391. Summarizes the evidence for the use of TPMT in dosing
thiopurine drugs and optimizing thiopurine therapy and states dosing recommendations based on
TPMT genotype. [PubMed: 21270794]
15▪. Duley JA, Somogi AA, Martin JH. The future of thiopurine pharmacogenenomics.
Pharmacogenomics. 2012; 13(14):1549–1552. Discusses the pharmacogenomic potential of
candidate genes to modify the prescription of thiopurine drugs. Our work identified top SNPs in
some of these genes which were associated with metabolite concentrations in UK acute
lymphoblastic leukemia patients. [PubMed: 23148628]
16. Krishnamurthy P, Schwab M, Takenaka K, et al. Transporter-mediated protection against
thiopurine-induced hematopoietic toxicity. Cancer Res. 2008; 68(13):4983–4989. [PubMed:
18593894]
Matimba et al. Page 13
Pharmacogenomics. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
17. Janke D, Mehralivand S, Strand D, et al. 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl)
adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4.
Hum Mutat. 2008; 29(5):659–669. [PubMed: 18300232]
18. Ansari M, Sauty G, Labuda M, et al. Polymorphisms in multidrug resistance-associated protein
gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009;
114(7):1383–1386. [PubMed: 19515727]
19▪. Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate
pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment
for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009; 85(2):164–172. Highlights the
influence of SNPs in thiopurine pathways genes, other than TPMT, on thiopurine toxicity.
[PubMed: 18685564]
20. Hawwa AF, Millership JS, Collier PS, et al. Pharmacogenomic studies of the anticancer and
immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008;
66(4):517–528. [PubMed: 18662289]
21. Han S, Lee KM, Park SK, et al. Genome-wide association study of childhood acute lymphoblastic
leukemia in Korea. Leuk Res. 2010; 34(10):1271–1274. [PubMed: 20189245]
22. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are
associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009; 41(9):1006–
1010. [PubMed: 19684604]
23. Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute
lymphoblastic leukemia. Nat Genet. 2009; 41(9):1001–1005. [PubMed: 19684603]
24. Horinouchi M, Yagi M, Imanishi H, et al. Association of genetic polymorphisms with
hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatr
Hematol Oncol. 2010; 27(5):344–354. [PubMed: 20670164]
25. Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation
associated with treatment response in childhood acute lymphoblastic leukemia. JAMA. 2009;
301(4):393–403. [PubMed: 19176441]
26. Yang JJ, Cheng C, Devidas M, et al. Genome-wide association study identifies germline
polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood. 2012;
120(20):4197–4204. [PubMed: 23007406]
27. Stocco GS, Yang W, Crews KR, et al. PACSIN2 polymorphism influences TPMT activity and
mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet. 2012; 21(21):4793–4804.
[PubMed: 22846425]
28. Li L, Fridley B, Kalari K, et al. Gemcitabine and cytosine arabinoside cytotoxicity: association
with lymphoblastoid cell expression. Cancer Res. 2008; 68(17):7050–7058. [PubMed: 18757419]
29. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical
translation. Pharmacogenomics. 2012; 13(1):55–70. [PubMed: 22176622]
30▪▪. Li F, Fridley BL, Matimba A, et al. Ecto-5′-nucleotidase and thiopurine cellular circulation:
association with cytotoxicity. Drug Metab Dispos. 2010; 38(12):2329–2338. Demonstrates the
intercellular cycling of thiopurines by the ABC and SLC transporter proteins and illustrates how
the impaired function of these transporters (specifically SNPs in ABCC4 and SLC28A3) can
result in the accumulation of toxic drug metabolites. [PubMed: 20855458]
31▪. Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of
musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010;
28(31):4674–4682. Demonstrates the use of genome-wide association study-informed functional
genomics in cancer therapeutics. [PubMed: 20876420]
32. Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively
regulating Akt. Cancer Cell. 2009; 16(3):259–266. [PubMed: 19732725]
33. Hou J, Wang L. FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of
pancreatic cancer. PLoS ONE. 2012; 7(5):e36252. [PubMed: 22590527]
34. Liu M, Ingle JN, Fridley BL, et al. TSPYL5 SNPs: association with plasma estradiol concentrations
and aromatase expression. Mol Endocrinol. 2013; 27(4):657–670. [PubMed: 23518928]
Matimba et al. Page 14
Pharmacogenomics. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
35. Li L, Fridley BL, Kalari K, et al. Gemcitabine and arabinosylcytosine pharmacogenomics:
genome-wide association and drug response biomarkers. PLoS ONE. 2009; 4(11):e7765.
[PubMed: 19898621]
36. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background
adjustment for oligonucleotide expression arrays. J Am Stat Assoc. 2004; 99(468):909–917.
37. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with
prednisolone for childhood acute lymphoblastic leukaemia: results of the UK medical research
council ALL97 randomized trial. Br J Haematol. 2005; 129(6):734–745. [PubMed: 15952999]
38. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of human red blood cell
thiopurine methyltransferase activity. J Chromatogr. 1994; 661(1):25–33.
39. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and
nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine
nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J
Chromatogr. 1992; 583(1):83–90. [PubMed: 1484095]
40. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase
pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997; 62(1):60–73.
[PubMed: 9246020]
41. Relling MV, Pui CH, Evans E. Thiopurine methyltransferase in acute lymphoblastic leukaemia.
Blood. 2006; 107(2):843–844. [PubMed: 16401827]
42. Kim H, Kang HJ, Kim HJ, et al. Pharmacogenetic analysis of prediatric patients with acute
lymphblastic leukaemia: a possible association between survival rate and ITPA polymorphism.
PLoS ONE. 2012; 7(9):e45558. [PubMed: 23029095]
43. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A. The ITPA c.94C>A and g IVS2+21A>C
sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta. 2007;
1772(1):96–102. [PubMed: 17113761]
44. Schmiegelow K, Forestier E, Kristinsson J, et al. Thiopurine methyltransferase activity is related to
the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92
study. Leukemia. 2009; 23(3):557–564. [PubMed: 18987654]
45. Jones TS, Yang W, Evans WE, Relling MV. Using HapMap tools in pharmacogenomic discovery:
the thiopurine methyltransferase polymorphism. Clin Pharmacol Ther. 2007; 81(5):729–734.
[PubMed: 17329987]
46. Niu N, Qin Y, Fridley BL, et al. Radiation pharmacogenomics: a genome-wide association
approach to identify radiation response biomarkers using human lymphoblastoid cell lines.
Genome Res. 2010; 20(11):1482–1492. [PubMed: 20923822]
47. Liu M, Wang L, Bongartz T, et al. Aromatase inhibitors, estrogens and musculoskeletal pain:
estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Breast Cancer Res. 2012; 14(2):R41. [PubMed: 22405131]
Website
101. PharmGKB. www.pharmgkb.org
Matimba et al. Page 15
Pharmacogenomics. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Executive summary
Aim
• We investigated candidate genes associated with the clinical response to
thiopurine drugs in the treatment of childhood lymphoblastic leukemia (ALL).
‘Human variation panel’ 6-thioguanine & 6-mercaptopurine cytotoxicity genome-
wide association study
• Genome-wide SNP association studies for 6-thioguanine (6-TG) and 6-
mercaptopurine (6-MP) cytotoxicity in lymphoblastoid cell lines (LCLs)
identified 289 SNPs. Only six were common to both 6-TG and 6-MP.
• The LCL top SNPs, along with tagSNPs for genes in the thiopurine pathway (a
set of genes involved in the metabolism and intercellular transport of thiopurine
drugs) were used for genotyping clinical samples.
Association analysis for UK ALL97 patients
• Thiopurine pathway genes, especially the ABC transporters but also SNPs in
genes influencing thiopurine metabolite formation (IMPDH1, ITPA and XDH),
were associated with disease relapse and overall survival.
• The ABC and SLC transporter SNPs were also associated with intracellular
thiopurine drug metabolite (6-thioguanine nucleotides and 6-
methylmercaptopurine nucleotides) concentrations and TPMT activity.
• In addition, nonthiopurine pathway genes (ATP6AP2, FRMD4B, GNG2,
KCNMA1 and NME1) were associated with these clinical phenotypes (disease
relapse, overall survival, thiopurine metabolite formation; p < 0.01).
Candidate gene functional validation
• Knockdown studies of candidate genes showed significant shifts in cytotoxicity
that resulted in altered resistance to 6-MP and/or 6-TG.
Conclusion
• The clinical response to thiopurines is regulated by a number of genes involved
in thiopurine metabolism and recirculation in addition to novel genes outside of
the known thiopurine pathways.
• siRNA knockdown of nonthiopurine candidate genes resulted in increased
resistance, or sensitivity, to thiopurine drug-induced cytotoxicity. The possible
mechanisms responsible for these observations should be pursued.
• Variation in the clinical response to thiopurines may be regulated by a panel of
thiopurine pathway and nonpathway genes; no novel candidates with large
effect size were identified in these studies.
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Figure 1. Genome-wide association studies for SNP associations with thiopurine IC50 values in
lymphoblastoid cell lines
Manhattan plots for lymphoblastoid cell line GWAS for IC50 values for (A) 6-TG and (B) 6-
MP. (C) Overlap of top SNPs for 6-TG and 6-MP with p-values of <10−4. The blue line
denotes p < 1 × 10−4; SNPs with an association <1 × 10−4 were considered for further study.
Red dots denote thiopurine pathway SNPs.
6-MP: 6-mercaptopurine; 6-TG: 6-thioguanine; GWAS: Genome-wide association study.
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Figure 2. Selection of SNPs for genotyping samples from acute lymphoblastic leukemia patients
(A) Top SNPs associated with 6-TG and 6-MP IC50 values in LCLs. Additional SNPs in a
region of chromosome 17 were selected from the CEU Hapmap2 data over approximately
380 kb extending across a SNP ‘signal’ on chromosome 17 that was observed during the
LCL GWAS for 6-MP IC50 value. (B) Thiopurine pathway SNPs. These SNPs were in or
near genes (<200 kb) encoding proteins known to be involved in the thiopurine pathway as
defined by PharmGKB.
6-MP: 6-mercaptopurine; 6-TG: 6-thioguanine; GWAS: Genome-wide association study;
LCL: Lymphoblastoid cell lines.
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Figure 3. Functional validation of candidate genes in cancer cell lines
(A) ‘Nonthiopurine pathway’ genes. (B) Thiopurine pathway genes. Cytotoxicity curves
after gene knockdown followed by drug treatment are shown for top candidate genes that
showed consistent ‘shifts’ in at least two cell lines. In this screening test best fit parameters
of a four parameter nonlinear regression model were calculated and statistical significance
was calculated. p-values are indicated if they were <0.05. In cases where the curves did not
fit the model (GNG2 and KCNMA1 in U87M cells and NME1 in U251 cells, all for 6-TG
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cytotoxicity) the curves could not be compared therefore p-values could not be calculated
although a clear curve shift can be observed.
6-MP: 6-mercaptopurine; 6-TG: 6-thioguanine.
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Table 1
Demographic data for the 589 UK ALL97 Caucasian children studied.
Variable Name or value n (%) or value (range)
Gender Male 330 (56.0)
Female 259 (44.0)
Age, median (range) – 4 (1–16)
WBC group <10 250 (42.4)
10–19.9 88 (14.9)
20–50.9 101 (17.1)
50–99.9 63 (10.7)
100+ 87 (14.8)
Outcome, relapse Male 74
Female 43
Outcome, death Male 44
Female 39
6-MP† Sample number 258
Dose, mg/m2 75 (14–125)
Derived TGNs 377 (66–1928)
Derived MeMPNs 7698 (66–1928)
TPMT activity 14.1 (2.8–23)
6-TG† Sample number 217
Dose, mg/m2 40 (10–78)
Derived TGNs 2030 (96–6874)
TPMT activity 13.7 (0–21)
Genotype available Diagnosis only 219 (37.2)
Chemotherapy only 266 (45.2)
Diagnosis and chemotherapy 104 (17.7)
TPMT genotypes‡ *1/*1 530 (90)
*1/*3A 51 (8.7)
*1/*3C 5 (0.8)
*1/*2 1 (0.2)
*3A/*3A 1 (0.2)
*3C/*3C 1 (0.2)
Metabolite assay data are reported as pmol/8 × 108 red blood cells and TPMT activity as units/ml red blood cells.
†Summary of thiopurine assays during thiopurine maintenance chemotherapy. Values are listed as median (range).
‡Clinical association analysis was performed after adjustment for TPMT genotype.
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MeMPN: Methyl-mercaptopurine nucleotide metabolite; TGN: Thioguanine nucleotide; WBC group: White blood cell count at disease diagnosis
(×109/l).
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